Patents by Inventor Franck Rousseau

Franck Rousseau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
    Patent number: 10835506
    Abstract: Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: November 17, 2020
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Christopher F. Rose, Franck Rousseau
  • TREATMENT AND PREVENTION OF MUSCLE LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE
    Publication number: 20180221320
    Abstract: Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.
    Type: Application
    Filed: August 16, 2016
    Publication date: August 9, 2018
    Inventors: Christopher F. Rose, Franck Rousseau
  • CORRUGATED, OPEN-SLEEVE CONDUIT FOR USE PRINCIPALLY FOR AIRCRAFT
    Publication number: 20120318397
    Abstract: Conduit particularly, although not exclusively, suited for aircraft is described. The conduit may be flexible, have low bend radius achievable without twisting, and offer access along most or all of its length to wire and cable within. It also may combine open-sleeve and corrugated technologies to provide open-sleeve, corrugated textile conduit.
    Type: Application
    Filed: June 12, 2012
    Publication date: December 20, 2012
    Applicant: AERAZUR, S.A.
    Inventors: Franck ROUSSEAU, Yohan TENDRON
  • METHODS FOR TREATING HCV
    Publication number: 20110306541
    Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
    Type: Application
    Filed: June 10, 2011
    Publication date: December 15, 2011
    Applicant: Gilead Sciences, Inc.
    Inventors: William E. Delaney, IV, William A. Lee, David W. Oldach, Franck Rousseau
  • METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20100008867
    Abstract: The present invention relates to methods, uses, and compositions comprising the caspase inhibitor (R)-N-((2S,3S)-2-(fluoromethyl)-2-hydroxy-5-oxo-tetrahydrofuran-3-yl)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 19, 2009
    Publication date: January 14, 2010
    Applicant: Gilead Sciences, Inc.
    Inventors: Howard S. Jaffe, Hans C. Reiser, Franck Rousseau, Geoffrey Yuen
  • Combination Therapy to Treat Hepatitis B Virus
    Publication number: 20090247487
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Application
    Filed: June 12, 2009
    Publication date: October 1, 2009
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau
  • Combination therapy to treat hepatitis B virus
    Patent number: 7572800
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: August 11, 2009
    Assignee: Gilead Sciences, Inc.
    Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau
  • Combination therapy to treat hepatitis B virus
    Publication number: 20030158150
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Application
    Filed: February 25, 2003
    Publication date: August 21, 2003
    Applicant: Triangle Pharmaceuticals, Inc.
    Inventors: Phillip A. Furman, George R. Painter, David W. Barry, Franck Rousseau
  • Combination therapy to treat hepatitis B virus
    Patent number: 6528515
    Abstract: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
    Type: Grant
    Filed: November 2, 1999
    Date of Patent: March 4, 2003
    Assignee: Triangle Pharmaceuticals, Inc.
    Inventors: Phillip A. Furman, George R. Painter, III, David W. Barry, Franck Rousseau